Mostrar el registro sencillo del ítem

dc.contributor.authorMárquez Coello, María de las Mercedes 
dc.contributor.authorArizcorreta Yarza, Ana 
dc.contributor.authorRodríguez Pardo, María
dc.contributor.authorIllanes Álvarez, Francisco
dc.contributor.authorMárquez, Denisse
dc.contributor.authorCuesta Sancho, Sara
dc.contributor.authorGirón González, José Antonio 
dc.contributor.otherBiomedicina, Biotecnología y Salud Públicaes_ES
dc.contributor.otherMedicinaes_ES
dc.date.accessioned2021-09-09T09:36:07Z
dc.date.available2021-09-09T09:36:07Z
dc.date.issued2021-05
dc.identifier.issn2045-2322
dc.identifier.urihttp://hdl.handle.net/10498/25327
dc.description.abstractThe objective of this work was to identify predictive factors of fibrosis regression after direct antiviral agents (DAAs) in HCV-monoinfected and HIV/HCV-coinfected patients. This was a prospective study of HCV-monoinfected (n=20), HIV/HCV-co-infected (n=66) patients and healthy controls (n=15). Patients had started DAAs and achieved sustained virological response. Liver stiffness (LS) and serum concentrations of profibrotic transforming growth factor (TGF)-beta 1 and CXC chemokine ligand 4 (CXCL4) and antifibrotic HGF hepatocyte growth factor (HGF) were analyzed at baseline (M0) and 12 months after starting DAAs (M12). A M12 LS achievement of <= 9.5 kPa was considered the cutoff point to discharge from a liver clinic. The LS decrease from M0 to M12 was 34%. No significant differences were observed in LS decline between HCV- and HIV/HCV-infected individuals. Changes of serum CXCL4, TGF-beta 1 and HGF levels did not correlate with LS improvement. 16 out from 56 patients (28%) with a baseline LS>9.5 achieved a M12 LS <= 9.5. HCV-monoinfected and HIV/HCV coinfected patients experienced a significant reduction of LS after sustained virological response. This improvement did not correlate with changes in serum profibrotic or antifibrotic markers. A 29% of those with a baseline LS>9.5 achieved a LS under this cutoff point.es_ES
dc.formatapplication/pdfes_ES
dc.language.isoenges_ES
dc.publisherNATURE RESEARCHes_ES
dc.rightsAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.sourceSci Rep 11, 9824 (2021)es_ES
dc.titleModifications of liver stiffness and CXCL4, TGF-beta 1 and HGF are similar in HCV- and HIV/HCV-infected patients after DAAses_ES
dc.typejournal articlees_ES
dc.rights.accessRightsopen accesses_ES
dc.identifier.doi10.1038/s41598-021-89370-6


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución 4.0 Internacional
Esta obra está bajo una Licencia Creative Commons Atribución 4.0 Internacional